GleamWall
中文EN

NVCT Nuvectis Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1875558 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-98.8%
TTM EPS YoY-46.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-67.0%
ROA-57.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$27.37M$4.68M$4.11M$5.09M$5.77M$3.61M$3.68M$4.50M
SG&A expense$3.68M$2.51M$2.15M$2.53M$2.02M$2.98M$1.89M$1.95M
Operating income-$31.05M-$7.20M-$6.26M-$7.62M-$7.79M-$6.59M-$5.57M-$6.45M
Net income-$30.07M-$7.02M-$6.05M-$7.31M-$7.46M-$6.33M-$5.33M-$6.25M
EPS (basic)-1.02-0.30-0.26—-0.44-0.30-0.27—
EPS (diluted)-1.02-0.30-0.26—-0.44-0.30-0.27—
Weighted avg. shares (diluted)29.47M23.48M23.41M—22.72M21.37M19.94M—
Balance sheet
Cash & equivalents$140.71M$22.16M$25.13M$31.63M$35.44M$26.79M$29.86M$18.53M
Current assets$140.84M$22.38M$25.40M$31.71M$35.59M$27.01M$30.15M$18.61M
Total assets$140.84M$22.38M$25.40M$31.71M$35.59M$27.01M$30.15M$18.61M
Current liabilities$14.19M$13.29M$11.18M$13.30M$11.58M$10.13M$9.19M$8.89M
Total liabilities$14.19M$13.29M$11.18M$13.30M$11.58M$10.13M$9.19M$8.89M
Shareholders' equity$126.65M$9.08M$14.22M$18.41M$24.01M$16.87M$20.95M$9.71M
Shares outstanding34.39M26.69M26.53M25.68M25.64M23.88M23.63M19.50M
Cash flow statement
Operating cash flow-$25.28M-$4.53M-$6.51M-$3.97M-$4.49M-$3.37M-$4.17M-$2.46M
Investing cash flow——$0———$0—
Financing cash flow$143.82M$1.56M$7,000$166,000$13.14M$296,000$15.51M$3.83M
Stock-based compensation$2.42M$1.71M$1.85M$1.48M$1.46M$1.73M$1.37M$1.14M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.